Thus, Basak and coworkers used an FDA-approved, turmeric-derived, curcumin-based formulation, APG-157DS, in a placebo-controlled human trial for oral cancer to demonstrate a reduction in pro-tumor cytokines IL-1β, IL-6, and IL-8 in the salivary supernatant fluid of patients with cancer. This evidence concerns the gene IL6 and cancer.